Key Points
- Hinge Health CFO James Budge sold 5,906 shares on May 11 at an average price of $54.82, totaling about $323,767. The sale was made under a pre-arranged Rule 10b5-1 plan, and Budge still owned 386,293 shares afterward.
- The company posted strong quarterly results, with earnings of $0.45 per share versus the $0.12 consensus estimate and revenue of $182.31 million, up 47.2% year over year. Despite the beat, Hinge Health remains unprofitable on a net basis.
- Wall Street remains broadly optimistic, with analysts assigning a consensus “Moderate Buy” rating and an average price target of $67.40. Several firms recently reiterated bullish views, including Piper Sandler and Citigroup.
Hinge Health Inc. (NYSE:HNGE - Get Free Report) CFO James Budge sold 5,906 shares of Hinge Health stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $54.82, for a total transaction of $323,766.92. Following the transaction, the chief financial officer directly owned 386,293 shares in the company, valued at $21,176,582.26. This represents a 1.51% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
James Budge also recently made the following trade(s):
- On Monday, March 23rd, James Budge sold 11,006 shares of Hinge Health stock. The shares were sold at an average price of $42.26, for a total transaction of $465,113.56.
Hinge Health Price Performance
Shares of NYSE:HNGE opened at $55.17 on Wednesday. Hinge Health Inc. has a 1-year low of $30.08 and a 1-year high of $62.18. The company has a market capitalization of $4.35 billion and a P/E ratio of -4.47. The firm's 50 day simple moving average is $43.58 and its two-hundred day simple moving average is $44.12.
Hinge Health (NYSE:HNGE - Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.33. Hinge Health had a negative net margin of 78.95% and a negative return on equity of 310.62%. The business had revenue of $182.31 million for the quarter. During the same period in the prior year, the firm earned $1.30 EPS. Hinge Health's revenue for the quarter was up 47.2% compared to the same quarter last year. On average, sell-side analysts anticipate that Hinge Health Inc. will post 0.78 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several equities analysts have weighed in on the stock. Piper Sandler reaffirmed an "overweight" rating and set a $95.00 price target on shares of Hinge Health in a report on Wednesday, May 6th. Freedom Capital upgraded shares of Hinge Health to a "strong-buy" rating in a research report on Thursday, January 22nd. Citigroup restated an "outperform" rating on shares of Hinge Health in a research report on Wednesday, May 6th. Royal Bank Of Canada raised their target price on shares of Hinge Health from $55.00 to $65.00 and gave the company an "outperform" rating in a research note on Wednesday, May 6th. Finally, Weiss Ratings raised shares of Hinge Health from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $67.40.
Check Out Our Latest Stock Report on Hinge Health
Hedge Funds Weigh In On Hinge Health
Several institutional investors have recently bought and sold shares of HNGE. BIT Capital GmbH grew its stake in Hinge Health by 79.3% during the fourth quarter. BIT Capital GmbH now owns 3,316,101 shares of the company's stock valued at $154,033,000 after acquiring an additional 1,466,577 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Hinge Health by 110.5% in the fourth quarter. Vanguard Group Inc. now owns 2,605,532 shares of the company's stock valued at $121,027,000 after purchasing an additional 1,367,693 shares in the last quarter. Tiger Global Management LLC grew its holdings in shares of Hinge Health by 227.1% in the fourth quarter. Tiger Global Management LLC now owns 1,805,751 shares of the company's stock valued at $83,877,000 after purchasing an additional 1,253,743 shares in the last quarter. Marshall Wace LLP bought a new stake in Hinge Health in the fourth quarter worth $54,469,000. Finally, Millennium Management LLC raised its stake in Hinge Health by 225.0% during the fourth quarter. Millennium Management LLC now owns 1,479,642 shares of the company's stock valued at $68,729,000 after purchasing an additional 1,024,317 shares in the last quarter.
Hinge Health Company Profile
(
Get Free Report)
Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company's platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.
Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
